Serum Institute of India, which is manufacturing the coronavirus vaccine Covishield being developed by the Oxford University along with pharma major AstraZenca, today said it will stop the Phrase 3 trials that were to begin in India next week. The vaccine trial was stopped across four nations as a precautionary measure after one of the recipients in the UK showed some potentially adverse symptoms.
The Serum Institute was issued a showcause by the country’s drug controller DCGI yesterday, where it was questioned why it was continuing the trials in India even though it has been stopped elsewhere.
“We are reviewing the situation and pausing India trials till AstraZeneca restarts the trials,” read a statement from the Serum Institute, which was still doing the groundwork for the trial including listing volunteers.
“We are following DCGI’s instructions and will not be able to comment further on trials. You can connect with DCGI for more updates on this front,” added the statement released today by the institute headed by Adar Poonawalla.
AstraZeneca, the British-Swedish pharma giant, had said the volunteer had suffered “an unexplained illness” and such pauses in drug trials are “routine”.
- COVID-19 cases in India cross 46-lakh mark - September 12, 2020
- 5 Food Hacks to Manage Weight and Boost Immunity - September 11, 2020
- India Likely Had 6.4 Million Covid Cases By May, Says ICMR’s Sero Survey - September 11, 2020
- UNICEF appoints Ayushmann Khurrana as celebrity advocate for children’s rights campaign - September 11, 2020
- COVID-19 caseload in India breaches 45-lakh mark - September 11, 2020
- COVID-19 recoveries in India surge to 35,42,663 - September 11, 2020
- Vaccine Still Possible By Year-End Despite Trial Pause, Says AstraZeneca - September 10, 2020
- Patients Home Isolating Forces Closure Of Bengaluru’s Covid Care Centres - September 10, 2020
- Induction of Rafale jets into IAF crucial considering atmosphere on border: Rajnath - September 10, 2020
- Record 95,735 infections, 1,172 fatalities - September 10, 2020